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In the present study, we explore the role of decreased renal
function and a genetic polymorphism on the recently
discovered protein resistin, apparently able to inhibit hepatic
insulin action in mice. We also investigate possible links with
inflammation and the insulin resistance present in patients
with chronic kidney disease (CKD). This is a post hoc,
cross-sectional study comparing 239 prevalent CKD patients
with varying degrees of renal function impairment with an
age- and gender-matched randomly selected control group
of 25 individuals. Glomerular filtration rate (GFR) was
estimated by the mean of urea and creatinine clearance
(24-h urine samples) (n¼ 204) or by iohexol clearance
(n¼ 60). Plasma analysis of blood lipids, insulin, glucose,
inflammatory markers (high-sensitivity C-reactive protein,
interleukin-6, tumor necrosis factor-a, vascular cellular
adhesion molecule, intercellular adhesion molecule) and
resistin (kit from LINCO Research, St Charles, MS) was
performed using commercially available assays or routine
methods. Insulin resistance was estimated by quantitative
insulin-sensitivity check index (QUICKI) and homeostasis
model assessment for insulin resistance (HOMA-IR) and
body composition by dual-energy X-ray absorptiometry.
Genotyping of a C/G promoter single nucleotide
polymorphism (n¼ 168) at position 180 of the resistin
gene was performed by PyroSequencingTM. Serum levels of
resistin were markedly elevated in the CKD patients with
both advanced (39.971.3 ng/ml) and mild to moderate
(23.271.0 ng/ml) renal function impairment, as compared
to controls (8.570.7 ng/ml; Po0.001). In a multiple linear
regression model in patients (adjusted r2¼ 0.60), only GFR
(b¼ 3.4; Po0.0001), lean body mass (b¼ 2.2; Po0.001) and
the inflammatory markers were independently associated
with circulating resistin levels. There was a weak but
significant impact of 180 C/G genotype on plasma levels of
resistin (median 43.072.4 ng/ml in CC, 37.572.0 ng/ml in CG,
and 41.174.9 ng/ml in GG; Po0.05). Univariate analysis of
non-diabetic patients and controls showed that serum
resistin was associated with markers of glucose metabolism.
However, in a multiple regression model, resistin, as well as
all the measured markers of inflammation, was only
associated with insulin resistance if GFR was not taken into
account. Circulating resistin levels are strongly associated
with both GFR and inflammatory biomarkers in CKD. As the
significant relationship between plasma resistin levels and
insulin resistance was lost following the correction for GFR,
resistin is not a likely mediator of insulin resistance in
patients with CKD. Renal function is an important factor to
take into account in clinical studies relating insulin sensitivity
to inflammatory biomarkers in CKD as well as in patients with
diabetes mellitus, who often have an impaired renal function.
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Insulin resistance is the central pathophysiological process of
the metabolic syndrome,1 a well-established and major risk
factor for the development of cardiovascular disease.1,2
Chronic kidney disease (CKD) of any etiology is associated
with insulin resistance of primarily peripheral tissues
resulting in varying degrees of hyperinsulinemia and glucose
intolerance.3,4 Decreased response to insulin is manifest
already in mild renal dysfunction5 and progresses with
declining glomerular filtration rate (GFR),3,6 only to improve
slightly at the initiation of renal replacement therapy.3,6 The
proposed link(s) between declining renal function and
insulin resistance appear to act mainly in peripheral tissues,3
but the exact mechanisms have so far not been clarified,7 and
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a variety of possible etiologies are proposed. Recent studies
have implicated acidosis,5 the effects of chronic systemic
inflammation,8 changes in body composition8,9 and accumu-
lation of free fatty acids10 as well as uremic carbamoylation
of signalling proteins11 as possible mechanisms.
In this context, the recent discovery of resistin, a 12.5-kDa
cysteine-rich protein secreted mainly by adipocytes and
apparently inhibiting insulin action in vitro,12–14 has
generated much interest. Resistin, like adiponectin, circulates
in serum in at least two distinct dimeric assembly forms that
appear to have different levels of bioactivity.15 Administra-
tion of recombinant resistin to mice impairs glucose
tolerance and decreases the action of insulin, whereas an
increase in insulin sensitivity is noted when the animals are
treated with resistin-neutralizing antibodies.12 Also, genetic
studies in humans suggest that a polymorphism in the
promoter region of the resistin gene can affect transcription
factor binding,16 thus influencing mRNA levels16,17 and may
be associated with glucose intolerance in obese indi-
viduals.18,19 The role of this polymorphism has not yet been
investigated in CKD.
Although several studies12,20 implicate resistin as an
important regulator of glucose levels in mice, the role of
resistin in human syndromes of insulin resistance, such as
uremia, is far from clear.12,21–23 Indeed, the few studies24–26
that have so far been performed in non-renal patients have
been unable to find a significant relationship between serum
glucose levels or markers of insulin resistance and circulating
resistin or resistin expression by subcutaneous adipocytes.
Similar results were observed in a small study of 30 CKD
patients by Kielstein et al.21
We thus hypothesized that increased levels of resistin due
to decreased GFR and increased inflammatory activity in
CKD may be one factor behind the insulin resistance
syndrome present in these patients. In order to test this
hypothesis, we performed a post hoc, cross-sectional study
including 239 prevalent CKD patients with varying degrees of
renal function impairment and compared them to an age-
and gender-matched randomly selected control group of 25
individuals. Furthermore, we also investigated the impact of a
common promoter polymorphism13,16 in the gene encoding
resistin in a subset (n¼ 168) of the patients with CKD.
RESULTS
Baseline characteristics
Baseline characteristics of the investigated patients and
controls are summarized in Table 1. There were no significant
differences in gender distribution between either of the
groups, but the control group tended (P¼ 0.06) to be older.
In CKD 3–4 as well as in CKD 5, inflammation (C-reactive
protein (CRP) X10 mg/l) was significantly more prevalent
than in the control group, whereas malnutrition (subjective
global assessment 41) was more prevalent only in CKD 5
patients as compared to the other groups (36 vs 6 and 4%
respectively; Po0.001). By definition, mean GFR was
significantly lower in CKD 3–4 (3072 ml/min) and CKD 5
patients (771 ml/min) than in the age- and gender-matched
controls (9073 ml/min).
Impact of decreasing GFR on resistin and inflammation
Serum levels of resistin were markedly elevated in CKD 5 patients
(39.971.3 ng/ml) as compared to both CKD 3–4 (23.271.0 ng/
ml; Po0.05) and controls (8.570.7 ng/ml; Po0.001). In
univariate analysis, serum resistin correlated well with GFR
(r¼0.54; Po0.001) (Figure 1). Measured inflammatory
markers also varied with the degree of renal failure, so that
CKD 5 patients had significantly higher median levels (inter-
leukin (IL)-6 5.8 ng/ml, high-sensitivity (hs)-CRP 6.7 mmol/l
and tumor necrosis factor-a (TNF-a) 9.6 pg/ml) when compared
to both CKD 3–4 patients (IL-6 3.2 ng/ml, hs-CRP 2.5 mmol/l
and TNF-a 9.0 pg/ml; Po0.05) and controls (IL-6 1.9 ng/ml,
hs-CRP 1.2 mmol/l and TNF-a 3.5 pg/ml; Po0.001).
Resistin vs inflammatory markers
In the total material, significant correlations between serum
levels of resistin and hs-CRP (r¼ 0.41; Po0.001), IL-6
(r¼ 0.37; Po0.0001) (Figure 2), leukocyte count (r¼ 0.49;
Po0.001), intercellular adhesion molecule (ICAM)-1
(r¼ 0.11; P¼ 0.06), vascular cellular adhesion molecule
(VCAM)-1 (r¼ 0.46; Po0.001), and TNF-a (r¼ 0.45;
Po0.0001) were found. Table 2 shows the correlations
between serum resistin levels and inflammatory markers in
CKD 5, CKD 3–4, and controls.
Correlation of resistin with body composition, blood lipids
and insulin resistance
In non-diabetics, but not in diabetics, resistin correlated only
weakly with lean body mass (LBM) (r¼0.14; Po0.05),
whereas there were no significant correlations between
resistin and total fat mass, truncal fat mass, weight or gender
in either diabetic or non-diabetic patients. Significant
associations between serum levels of resistin and triglycerides
(r¼ 0.15 in non-diabetics, r¼ 0.21 in diabetics; Po0.05) as
well as with high-density lipoprotein cholesterol (r¼0.16
in non-diabetics, r¼0.33 in diabetics; Po0.01) were
observed. There were no significant correlations between
resistin and total or low-density lipoprotein cholesterol in
either group. Univariate analysis of non-diabetic patients and
controls showed that serum levels of resistin were associated
with all measured markers of glucose metabolism. Thus,
serum resistin correlated with blood glucose (r¼ 0.13;
P¼ 0.05), plasma insulin (r¼ 0.27; Po0.001), and quanti-
tative insulin-sensitivity check index (QUICKI) (r¼0.31;
Po0.001) (Table 2 and Figure 3). The association between
serum resistin and QUICKI prevailed in a subgroup analysis
of CKD 5 patients without diabetes mellitus (r¼0.15;
Po0.05), but not in CKD 3–4 patients (r¼ 0.22; P¼NS) or
controls (r¼0.06; P¼NS) without diabetes mellitus.
QUICKI was also significantly associated with serum levels
of IL-6 (r¼0.31; Po0.001), hs-CRP (r¼0.31;
Po0.001), and TNF-a (r¼0.21; Po0.01) in univariate
analysis of the non-diabetic group.
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Table 1 | Clinical characteristics of patients with CKD and controls
CKD 5 CKD 3–4 Controls Significance
Number 204 35 24
Age (years) 5471 5472 5972 P=0.06
GFR (ml/min) 771 3072 9073 Not tested
Diabetes mellitus (%) 29 34 0 Po0.05
Malnutrition (%) 36 6 4 Po0.0001
Inflammation (%)a 35 11 0 Po0.0001
Males (%) 65 71 64 n.s.
Body composition
Body mass index (kg/m2) 24.570.3 25.970.7 24.870.6 n.s.
LBM (kg)b 49.570.7 54.271.7 50.271.7 n.s.
Total fat mass (kg)b 21.570.7 25.371.6 22.371.4 n.s.
Truncal fat mass (kg)b 11.570.4 14.270.9 11.770.9 Po0.05
Markers of glucose metabolism
Fasting plasma glucose (mmol/l) 6.670.3 5.870.3 5.170.2 n.s.
Fasting plasma insulin (mU/l) 20.671.1 14.171.1 6.971.0 Po0.0001
Hemoglobin A1c (%) 5.570.1 5.770.3 4.770.1 Po0.01
Serum resistin (ng/ml) 39.971.3 23.271.0 8.570.7 Po0.0001
QUICKI 0.570.01 0.670.01 0.770.02 Po0.0001
HOMA-IR 6.870.7 3.770.5 1.770.3 Po0.0001
Serum lipids
Fasting serum cholesterol (mmol/l) 5.570.1 5.470.2 5.170.1 n.s.
Fasting serum triglycerides (mmol/l) 2.270.1 2.170.2 1.470.1 Po0.0001
Fasting serum high-density lipoprotein cholesterol (mmol/l) 1.270.1 1.370.1 1.570.1 Po0.01
Inflammatory biomarkers
Serum hs-CRP (mmol/l)c,d 6.7 (0.2–163.0) 2.5 (0.3–49.0) 1.2 (0.2–6.7) Po0.0001
Serum IL-6 (pg/ml)c,e 5.8 (0.8–35.1) 3.2 (0.8–9.6) 1.9 (0.4–6.7) Po0.0001
Serum TNF-a (pg/ml)c,f 9.6 (3.1–81.8) 9.0 (4.7–27.8) 3.5 (1.6–10.6) Po0.0001
Serum ICAM-1 (ng/ml)c,f 1352738 940741 690731 Po0.001
Serum VCAM-1 (ng/ml)c,f 26977 26678 229710 P=0.06
Blood leukocytes (109/l) 8.770.3 7.570.3 6.270.3 Po0.001
CKD, chronic kidney disease; GFR, glomerular filtration rate; HOMA-IR, homeostasis model assessment for insulin resistance; IC, leukocyte count; ICAM-1, intercellular adhesion
molecule-1; LBM, lean body mass; QUICKI, quantitative insulin-sensitivity check index; TNF-a, tumor necrosis factor-a; VCAM-1, vascular cellular adhesion molecule-1.
Mean7s.e.m. or median (range) indicated. n.s.: not significant.
aCRPX10 mg/l.
bn=186/35/24.
cMedian and range.
dn=195/28/24.
en=162/35/24.
fn=175/34/24.
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Figure 1 | Correlation between GFR and plasma resistin levels in
204 CKD 5 patients (K; q¼0.16; Po0.05), 35 CKD 3–4 patients
(o; q¼0.63; Po0.001), and 24 age- and gender-matched
controls (D; q¼0.21; Po0.01).
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Figure 2 | Correlation between plasma IL-6 and plasma resistin
levels in 204 CKD 5 patients (K), 35 CKD 3–4 patients (o), and 24
age- and gender-matched controls (D). Analyzed separately, there
was a significant correlation between IL-6 and resistin in CKD 5
patients (r¼ 0.20; Po0.01) but not in CKD 3–4 patients or in controls.
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Impact of genotype
The promoter 180 C/G single nucleotide polymorphism
(SNP) was analyzed in 168 of the CKD 5 patients as well as in
205 controls. The genotype frequencies were CC 48%
(n¼ 80), CG 45% (n¼ 76), GG 7% (n¼ 12) in CKD 5
patients and CC 47% (n¼ 97), CG 42% (n¼ 85) and GG
11% (n¼ 23) in the genetic controls. The allele frequencies
were 0.70 for the C allele in CKD patients and 0.68 in
controls, and the genotype frequencies did not deviate from
Hardy–Weinberg equilibrium in either patients or controls.
Patients who were CG heterozygotes had significantly lower
plasma resistin levels as compared to CC carriers (Kruskall–-
Wallis; Po0.05) (Figure 4). The mean resistin plasma levels
for each genotype were 43.072.4 ng/ml in CC, 37.572.0 ng/
ml in CG, and 41.174.9 ng/ml in GG.
Multivariate analysis
In a multiple linear regression model (adjusted r2¼ 0.16)
(Table 3) including factors significantly associated with
resistin in univariate analysis, as well as age and gender,
Table 2 | Correlation matrix (Spearman’s rank) for markers of glucose metabolism and inflammatory biomarkers with serum
resistin levels
CKD 5 CKD 3–4 Controls
Serum resistin (ng/ml) Serum resistin (ng/ml) Serum resistin (ng/ml)
All patients and controls (204 CKD 5 patients, 35 CKD 3–4 patients and 24 controls)
Markers of glucose metabolism
Fasting plasma insulin (mU/l) 0.10 0.19 0.02
Fasting plasma glucose (mmol/l) 0.09 0.28 0.20
QUICKI 0.15* 0.22 0.06
Hemoglobin A1c (%) 0.12* 0.19 0.03
Markers of inflammation
Blood leukocytes (109/l)a 0.41*** 0.52*** 0.18
Serum VCAM-1 (ng/ml)b 0.19** 0.36** 0.16
Serum ICAM-1 (ng/ml)b 0.16* 0.22 0.15
Serum hs-CRP (mg/l)c 0.22** 0.09 0.19
Serum TNF-a (pg/ml)d 0.25*** 0.37* 0.05
Serum IL-6 (ng/ml)e 0.20** 0.01 0.15
Non-diabetics (145 CKD 5 patients, 23 CKD 3–4 patients and 24 controls)
Markers of glucose metabolism
Fasting plasma insulin (mU/l) 0.10 0.33 0.07
Fasting plasma glucose (mmol/l) 0.09 0.33 0.20
QUICKI 0.18* 0.39 0.11
Hemoglobin A1c (%) 0.19* 0.25 0.19
Markers of inflammation
Blood leukocytes (109/l)a 0.40*** 0.53** 0.18
Serum VCAM-1 (ng/ml)b 0.17** 0.08 0.13
Serum ICAM-1 (ng/ml)b 0.15 0.08 0.17
Serum hs-CRP (mg/l)c 0.16 0.17 0.19
Serum TNF-a (pg/ml)d 0.15 0.45* 0.05
Serum IL-6 (ng/ml)e 0.21** 0.08 0.16
Diabetics (59 CKD 5 patients and 12 CKD 3–4 patients)
Markers of glucose metabolism
Fasting plasma insulin (mU/l) 0.09 0.01 Not tested
Fasting plasma glucose (mmol/l) 0.05 0.30 Not tested
QUICKI 0.11 0.08 Not tested
Hemoglobin A1c (%) 0.05 0.13 Not tested
Markers of inflammation
Blood leukocytes (109/l)a 0.43*** 0.51 Not tested
Serum VCAM-1 (ng/ml)b 0.16** 0.23 Not tested
Serum ICAM-1 (ng/ml)b 0.19 0.20 Not tested
Serum hs-CRP (mg/l)c 0.31* 0.13 Not tested
Serum TNF-a (pg/ml)d 0.45*** 0.28 Not tested
Serum IL-6 (ng/ml)e 0.24 0.11 Not tested
CKD, chronic kidney disease; GFR, glomerular filtration rate; HOMA-IR, homeostasis model assessment for insulin resistance; IC, leukocyte count; ICAM-1, intercellular adhesion
molecule-1; LBM, lean body mass; QUICKI, quantitative insulin-sensitivity check index; TNF-a, tumor necrosis factor-a; VCAM-1, vascular cellular adhesion molecule-1.
*Po0.05; **Po0.01; ***Po0.001.
an=125/23/24.
bn=204/35/24.
cn=195/28/24.
dn=175/34/24.
en=162/35/24.
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and entering the different inflammatory markers one at a
time, only GFR (b¼ 4.3; Po0.0001) and the different
inflammatory markers (only data for hs-CRP shown) were
significantly associated with circulating resistin levels. In two
separate multiple linear regression models, we also investi-
gated independent associations with QUICKI as a marker of
insulin resistance in non-diabetic patients as shown in
Table 4.
DISCUSSION
The present study demonstrates that circulating plasma
resistin levels, like other adipokines such as leptin and
adiponectin,27,28 are markedly elevated in patients with renal
function impairment. Several factors may contribute to
elevated circulating resistin levels in CKD. First, we
demonstrate a strong impact of GFR on circulating fasting
plasma levels of resistin (Figure 1 and Table 3). Thus, our
data confirm the association previously reported by Kielstein
et al.21 in a smaller cohort of CKD patients. As resistin is a
12.5 kDa protein, it could be hypothesized that this small
protein will have similar renal clearance characteristics as
b2-microglobulin (13.7 kDa), which has been extensively
studied.29 If this is true, it may be expected that resistin
secretion through the kidneys is the major pathway of
elimination, and current dialysis techniques will only
partially be able to remove excess resistin from the
circulation. Contrary to what has been reported in non-
renal patients,30,31 we found no significant relationship
between truncal or total fat mass (by dual-energy X-ray
absorptiometry) and resistin levels. In this regard, resistin
appears to differ from leptin and adiponectin, which both are
related to fat mass also in CKD patients.27,28 Clearly, in future
clinical studies evaluating circulating resistin levels, renal
function must be taken into account.
Another major finding of the present study is the
association between serum levels of resistin and various
biomarkers of inflammation, confirming studies in patients
without renal function impairment.32–35 Recently, it has
become apparent that CKD is a state of chronic inflammation
that is associated with significant increases in serum
proinflammatory cytokine levels already at moderate levels
of renal function impairment.36,37 Although fat mass is likely
an important source of both resistin and several pro-
inflammatory cytokines,9 other links between inflammation
and resistin are also likely present. First, in cultured human
vascular endothelial cells, resistin is able to induce expression
of adhesion molecules VCAM-1 and ICAM-1, an effect that is
inhibited by adiponectin.33 Indeed, in the present study,
strong positive associations were found between resistin and
both ICAM and VCAM levels. Furthermore, resistin mRNA is
abundant in human primary acute leukemia cells and in
myeloid cell lines,22 indicating a hitherto unidentified
biological function of resistin in leukocytes. Indeed, Patel
et al.35 found that resistin is more expressed in bone marrow
than in adipose tissue. Moreover, in vitro studies have
demonstrated resistin mRNA expression in peripheral blood
3
4
5
6
7
8
9
10
20
30
40
50
60
70
80
90
100
200
Resistin (ng/ml)
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
QU
IC
KI
=0.09 
P<0.001
Figure 3 | Correlation between plasma resistin levels and insulin
resistance as estimated by QUICKI in 145 CKD 5 patients (K), 23
CKD 3–4 patients (o) and 24 age- and gender-matched controls
(D), all without diabetes mellitus. Analyzed separately, there was a
significant correlation between IL-6 and resistin in CKD 5 patients
(r¼0.15; Po0.05) but not in CKD 3–4 patients or in controls.
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Figure 4 | The impact of genotype on serum resistin levels in 168
CKD 5 patients.
Table 3 | Stepwise, forward followed by backward,
multivariate linear regression analysis of predictors of (log)
serum resistin in CKD 5 (n=204) and CKD 3–4 (n=35) patients
b Standard error P-value
Intercept 35.6 0.99 o0.001
GFR (CKD 3–4 vs CKD 5) 4.3 0.91 o0.001
Hs-CRP (o4.4/44.4 mg/l) 3.6 0.91 o0.001
The initial model included resistin as the dependent parameter and age (o54/454
years) and gender, as well as factors associated with resistin in univariate analysis,
that is, LBM (o51/451 kg), serum high-density lipoprotein cholesterol (o1.2/
41.2 mmol/l), blood leukocyte count (o7.7 10/47.7 109/l), hs-CRP (o4.4/
44.4 mg/l) and GFR (CKD 3–4 or CKD 5). The parameters were dichotomized by
median (GFR by CKD class).
Adjusted total r2=0.16.
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monocytes, with increased levels after stimulation by IL-1,
IL-6, and TNF-a, as well as with lipopolysaccharides.32,34
Finally, Reilly et al.38 have demonstrated that plasma resistin
levels are correlated with markers of inflammation and predict
coronary atherosclerosis in humans independently of CRP.
As the 180 G/C polymorphism in the promoter region
of the resistin gene can affect transcription factor binding16
and influence mRNA levels,16,17 it could be hypothesized that
this variation may also influence circulating plasma levels of
resistin in CKD. Although the present study demonstrated
significantly lower plasma resistin levels in 180 CG
heterozygotes (Figure 4), the clinical significance of this
polymorphism may be limited in this population. Further
studies must be performed to evaluate how genetic
polymorphisms in the resistin gene affect resistin plasma
levels in ESRD.
Since the discovery of resistin in 2001,12–14 the putative
association between resistin and insulin resistance has
attracted a lot of interest. In mice, resistin mRNA and
protein levels decline in parallel with glucose and insulin
during fasting and are restored after refeeding20 and adipose
resistin expression and serum resistin increase in response to
hyperinsulinemia and further in response to hyperglycemia.20
In obese mice, circulating resistin levels are significantly
elevated and positively correlated with insulin, glucose and
lipids,39 and mice lacking the resistin gene exhibit low blood
glucose levels after fasting due to reduced hepatic glucose
production. Interestingly, a recent study by Muse et al.40
suggests that this effect is mainly due to modulation of
hepatic insulin resistance. Although resistin seems to be
strongly associated with insulin resistance in mice models,
several recent studies have questioned the hypothesis that
resistin is a significant determinant of insulin resistance in
humans. First, Janke et al.24 found low levels of resistin
expression in subcutaneous adipocytes and no correlation
with insulin resistance. Similarly, Heilbronn et al.25 found
that serum resistin concentrations did not differ among
non-obese, obese and obese diabetic subjects, nor were they
significantly correlated with glucose metabolism during a
hyperinsulinemic glucose clamp across the groups. Finally,
when comparing three different immunoassays for resistin,
Pfutzner et al.26 found no correlation between fasting plasma
levels of resistin and any of the measured parameters of
insulin resistance or with blood lipids in patients with type II
diabetes mellitus. In the present study, a weak, but significant,
correlation between fasting serum resistin levels and two
surrogate markers of insulin resistance (HOMA and
QUICKI) was demonstrated in a univariate analysis of
non-diabetic CKD patients and controls. However, after
correction for GFR in a multivariate regression model
(Table 4), the association between resistin and QUICKI was
lost. Our results confirm those of Kielstein et al.,21 who found
no relationship between plasma levels of resistin and markers
of glucose metabolism, despite markedly elevated resistin
levels in CKD patients with IgA nephropathy.
A number of recent reports suggest that increased levels of
the acute-phase inflammatory markers, such as CRP, are
related to insulin resistance41,42 and the chronic low-grade
inflammation present in the metabolic syndrome has been
suggested to play an important role in the development of
this complication.43 Indeed, a recent report by Arkan et al.41
demonstrates that liver cell IkB kinase-b plays an important
role in modulating hepatic insulin resistance, whereas
myeloid cells may play a central role in the development of
systemic insulin resistance. In accordance with previous
studies in non-renal patients, we found significant associ-
ations between several biomarkers of inflammation and
QUICKI in multivariate analysis correcting for the impact of
diabetes mellitus and visceral fat mass (Table 4). However,
when also GFR was included in the model (Table 4), the
significant association between inflammation biomarkers and
QUICKI was lost. The reason(s) for this is far from clear, but
Table 4 | Impact of GFR on the correlation between QUICKI (as a surrogate marker of insulin resistance) and inflammation
Variable
Univariate
Multivariate model adjusted
for age, gender, truncal fat
mass, and diabetes mellitus
Multivariate model adjusted
for age, gender, truncal fat
mass, diabetes mellitus, and GFR
Spearman r P-value T-ratio P-value T-ratio P-value
Age (o54/454 years)a 0.05 n.s.
Gender 0.03 n.s.
GFR (ml/min) 0.21 o0.01
Truncal fat mass (o12/412 kg)a 0.27 o0.001
Diabetes mellitus (yes/no) 0.25 o0.001
Inflammatory biomarkersa
Hs-CRP (o4.4/44.4 mg/l) 0.20 o0.01 2.21 o0.05 1.34 n.s.
IL-6 (o5.8/45.8 ng/ml) 0.16 o0.05 1.94 0.05 0.94 n.s.
TNF-a (o9.45/49.45 pg/ml) 0.07 n.s. 0.10 n.s. 0.16 n.s.
VCAM-1 (o1194/41194 ng/ml) 0.08 n.s. 1.90 0.06 0.69 n.s.
ICAM-1 (o248/4248 ng/ml) 0.12 0.08 1.44 n.s. 1.64 n.s.
Resistin (o33.5/433.5 ng/ml) 0.20 o0.01 2.40 o0.05 1.22 n.s.
The three columns show first univariate correlations with continuous variables and then two multivariate linear regression models of predictors of QUICKI in CKD 5 (n=204)
and CKD 3–4 (n=35) patients, the second model correcting for GFR. The initial model was adjusted for age, gender, truncal fat mass and diabetes mellitus. We subsequently
added each inflammatory biomarker in turn, dichotomizing by median (shown below). In the second model, we also adjusted for GFR, which was dichotomized by CKD class
(CKD 3–4 vs CKD 5). n.s.: not significant.
aDichotomized by median.
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likely does not involve circulating resistin levels, which were
also not correlated with QUICKI in the second model
(Table 4). Clearly, as mild to moderate renal function
impairment is a common phenomenon in patients with
diabetes mellitus and the metabolic syndrome, future clinical
studies investigating a possible direct link between inflam-
mation biomarkers and insulin resistance should take GFR
into account.
Some shortcomings of the present study should be
addressed. First, it should be pointed out that this is a post
hoc analysis of CKD patients with mostly advanced renal
impairment. Clearly, this may limit the value of the study,
and further studies on patients with mild renal impairment
are needed. Second, although QUICKI has been reported to
be a valid surrogate marker also in this patient group,44 it
may not accurately reflect insulin resistance. However, it has
been postulated that resistin is mainly active in modulating
hepatic insulin resistance,40 making use of the euglycemic
clamp technique potentially also problematic as it is known
to measure mainly peripheral insulin resistance.45 Another
point of criticism might be that we do not know if resistin
levels in the present study represent active resistin or if an
accumulation of inactive resistin metabolites accounts for the
major part of the increased plasma resistin concentration
observed in CKD. Also, circulating resistin plasma levels may
not accurately reflect local resistin action at the tissue level.
Finally, the use of antihypertensive medication has been
reported to influence insulin sensitivity. Thus, while
b-blockers and thiazolidinediones appear to decrease insulin
sensitivity, most (but not all) ACE inhibitors and calcium
blockers appear to improve it.46 As the majority of these
patients are taking more than one class of drugs, we think
that this confounder is of minor importance and will not
unduly affect the reported results. Indeed, we could find no
significant differences in either QUICKI or HOMA-IR
between non-diabetic patients taking ACEI and those not
taking ACEI.
In summary, the present study demonstrates that whereas
circulating resistin levels are strongly associated with both GFR
and inflammatory biomarkers, the impact of the 180 G/G
promoter polymorphism in the resistin gene may be limited.
The present data support the hypothesis that inflammation is
associated with hyper-resistinemia. As the significant relation-
ship between plasma resistin levels and insulin resistance was
lost following the correction for GFR, resistin is not a likely
mediator of insulin resistance in patients with renal disease.
Finally, as the association between insulin resistance in non-
diabetic patients and inflammation was lost following the
correction for GFR, renal function is an important factor to
take into account when evaluating clinical studies relating
insulin sensitivity to inflammatory biomarkers.
MATERIALS AND METHODS
Patients
Altogether, 239 CKD patients (158 males; 66%) with a mean age of
5371 years were studied. Two hundred and four consecutive
patients with CKD stage 5 (GFRo15 ml/min; 65% males, mean age
5471 years) enrolled in the renal program at the Karolinska
University Hospital Huddinge between 1997 and 2004 and included
as participants of an ongoing prospective study, parts of which we
previously described,22–24 were used along with 35 prevalent (aged
5472 years; 71% males) patients with CKD 3–4 (GFR 15–60 ml/
min) included from the hospital renal outpatient clinic. The study
exclusion criteria were age below 18 years or above 70 years, clinical
signs of acute infection, active vasculitis or liver disease at the time
of evaluation or unwillingness to participate in the study. The causes
of CKD were chronic glomerulonephritis in 74 patients, diabetic
nephropathy in 38 patients, polycystic kidney disease in 17 patients
and other, or unknown, etiologies in 110 patients. Fifty-nine (25%)
patients were diagnosed as type I diabetics, defined as insulin
dependent from the outset, whereas 35 (15%) were diagnosed as
type II diabetics, defined as initially non-insulin-dependent diabetes
mellitus. In accordance with current therapy recommendations,
most (n¼ 33) of the patients initially taking oral antiglycemic agents
or on restricted diets had been switched to insulin therapy at the
time of inclusion in the study. The majority of patients were on
antihypertensive medications (angiotensin-converting enzyme
inhibitors and/or angiotensin II receptor antagonists, n¼ 117;
b-blockers, n¼ 127; calcium-channel blockers, n¼ 143) and other
commonly used drugs in CKD, such as phosphate and potassium
binders, diuretics, erythropoiesis-stimulating agents, iron substi-
tution and vitamin B, C, and D supplementation. Fourteen patients
were on lipid-lowering medication (HMG-CoA-reductase inhi-
bitors). The patients were divided into two groups according to the
degree of renal failure using the staging according to K/DOQI
Guidelines.21 The Ethics Committee of the Karolinska Institute
approved the study at the Karolinska University Hospital, Huddinge,
and informed consent was obtained from each patient.
Control subjects
A population-based randomly selected group of 24 control subjects
(16 males; 64%) with a median age of 60 years (range 37–78 years)
were used for comparative analyses of biochemical and metabolic
parameters. The control subjects were investigated according to a
similar protocol as the patient group. The random selection of
subjects in the Stockholm region was performed by Statistics Sweden
(SCB). No other exclusion criterion than unwillingness to participate
in the study was applied in the selection of the control group. Thus,
one control patient had type I diabetes mellitus and one was
considered malnourished by SGA. For comparison of genotype
distribution, a different control population consisting of 205
unrelated individuals living in Stockholm County and participating
in a study on the genetics of schizophrenia (62% males) with a mean
age of 40.1710 years (range 15–86 years) was used.
Measurement methods
After an overnight fast, venous blood samples were drawn and
stored at 701C for biochemical analyses. GFR was estimated by the
mean of creatinine and urea clearance, calculated from 24-h urinary
samples collected from the 204 CKD 5 patients, or as iohexol
clearance in the 35 CKD 3–4 patients as well as in the controls.
Plasma analysis for insulin was performed on an IMMULITEs
system (DPC Corp., Los Angeles, CA, USA) using commercially
available assays (from DPC Corp.) as were measurements of serum
ICAM-1 and serum VCAM-1 (R&D Systems Europe Ltd, Abingdon,
UK). The levels of serum cholesterol and triacylglycerols were
analyzed by standard enzymatic procedures (Roche Diagnostics
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GmbH). High-density lipoprotein cholesterol was determined after
precipitation of apolipoprotein (Apo) B-containing lipoproteins by
phosphotungstic acid. Plasma resistin levels were measured by a
commercially available high-sensitivity photometric enzyme-linked
immunosorbent assay (LINCO Research, St Charles, MS, USA).
The plates were read using enzyme-linked immunosorbent assay
VERSAmax readerTM (Molecular Devices Corporation, Sunnyvale, CA,
USA) and the data were analyzed with the SoftmaxPROs software
(Molecular Devices Corporation, Sunnyvale, CA, USA). Levels of Apo
A1 (Apo A) and Apo B were determined using an immunonephelo-
metric procedure (Behring AG, Marburg, Germany). Hs-CRP was
also analyzed using an immunonephelometric procedure (Behring
AG, Marburg, Germany), whereas the remaining biochemical analyses
were carried out using routine methods at the Department of Clinical
Chemistry at Karolinska University Hospital at Huddinge.
Nutritional status was recorded at the time of inclusion,
concurrent with the drawing of blood samples, as assessed subjective
global assessment.47,48 Body mass index was calculated as weight/
height2 (kg/m2). In non-diabetic patients, insulin resistance was
calculated by QUICKI (1/(log(fasting plasma insulin (mU/ml))þ
log(fasting plasma glucose (mmol/l))))49 as well as by the home-
ostasis model assessment for insulin resistance (HOMA-IR: fasting
serum insulin (mU/ml) fasting plasma glucose (mmol/l)/22.5).50
Insulin resistance was not assessed in diabetic subjects. LBM and
truncal fat mass were estimated by dual-energy X-ray absorptio-
metry using the DPX-L device (Lunar Corp., Madison, WI, USA).
With this technique, fat and LBM distribution are directly estimated
without making assumptions about the two-compartment model.
Dual-energy X-ray absorptiometry has proved superior to other
simple non-invasive methods for determining body composition in
renal failure, especially if repeated measurements are made.51
However, it must be kept in mind that, although the state of
hydration does not affect the estimate of fat mass with dual-energy
X-ray absorptiometry, it does affect that of LBM.
Genotyping method
The 180 C/G promoter SNP (rs1862513 in the NCBI SNP
database) was chosen for analysis based on previously published
findings.13,16,18,19,24 A 5 ml ethylenediaminetetraacetic acid sample
of peripheral blood was drawn, from which DNA was extracted
using the QIAamps DNA kit. Samples were stored at 201C if not
analyzed immediately. Sequence amplification was then performed
by the polymerase chain reaction (PCR) on a PTC-225 Thermo-
cycler (MJ Research Inc., Cambridge, MA, USA). PCR primers were
designed using the software Primer Designer 4s for Windows
(version 4.1) and were synthesized by Thermohybaids (Ulm,
Germany). The forward and reverse PCR primers were (50–30)
CGAGTCGTGTGATCATAAGTC and CCTGCGTTGCGTAATAAGTC,
respectively, and the reverse primer was biotinylated. The PCR reaction
volume was 50ml, containing 20 ng of DNA, 10 pmol of each forward
and reverse primer, 0.2 mM of each dNTP, 0.3 U of DyNAzymeTM II
(DNA Polymerase, Finnzymes Inc., CA, USA), 10 mM of Tris-HCl,
1.5 mM of MgCl2, 50 mM of KCl and 0.1 % of Triton X-100. The PCR
annealing temperature was 581C. The pyrosequencing reaction was
then performed on a PSQ96TM Instrument (Pyrosequencing AB,
Uppsala, Sweden) as described previously.51 The sequence primer used
was (50–30) ACCAGTCTCTGGACATGAAGA
Statistical analysis
Results are expressed as mean and s.e.m, unless otherwise indicated,
with Po0.05 indicating significance. Comparisons between the
groups were made using Kruskal–Wallis test. Comparisons between
groups for nominal variables were made using the w2 test. As many
values were not normally distributed, correlations between variables
were calculated according to Spearman’s rank correlation test.
Stepwise multivariate regression analysis was used to assess the
predictors of resistin and QUICKI. All analyses were performed
using statistical software SAS version 8.2 (SAS Campus Drive, Cary,
NC, USA), whereas Genepop (http://wbiomed.curtin.edu.au/gene-
pop/index.html) was used to test the genotype distributions for
Hardy–Weinberg equilibrium.
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